All About Polymyalgia Rheumatica and Temporal Arteritis: From Symptoms to Treatments: By Shreoshree Chakrabarty Polymyalgia rheumatica (PMR) and temporal arteritis, also known as giant cell arteritis ...

Polymyalgia rheumatica (PMR) is an inflammatory condition that causes widespread pain, stiffness, or aching in the large muscle groups, especially around the shoulders, hips, lower back, neck, and ...

Corticosteroids are the first-line treatment for the inflammatory condition polymyalgia rheumatica (PMR), working rapidly and effectively at easing symptoms like morning stiffness, muscle and joint ...

Polymyalgia rheumatica (PMR) is accepted as being the most common inflammatory disease in persons over the age of 50 years of European descent. The clinical features of PMR are myriad, and each of the ...

Polymyalgia rheumatica (PMR) is an inflammatory disorder of unknown aetiology that can be extremely disabling when active. Glucocorticoids are currently the therapy of choice for patients with PMR, ...

Polymyalgia rheumatica is a common inflammatory disease characterized by pain and stiffness in the shoulders and hips. Glucocorticoids are the first-line treatment, but relapses and ...

Polymyalgia rheumatica (PMR) is an inflammatory disorder that causes severe muscle pain, muscle stiffness, muscle spasms and cramping on both sides of the body, particularly in the shoulders, neck, ...

Polymyalgia rheumatica (PMR) is a common inflammatory disorder that causes pain, usually in your shoulders and upper body. Inflammation is your body’s natural response when it’s trying to protect you ...

Please provide your email address to receive an email when new articles are posted on . Patients were more likely to achieve sustained remission with sarilumab vs. placebo. The most common adverse ...

Background: Polymyalgia rheumatica is one of the most common inflammatory rheumatologic conditions in older adults. Other inflammatory rheumatologic disorders are associated with an excess risk of ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they ...

If approved, Cosentyx (secukinumab) will be first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica (PMR), providing new treatment option after steroids¹Recommendation based ...